The evolving landscape of first-line and subsequent therapies in EGFR-mutated NSCLC: efficacy, resistance, and tolerability
{{output}}
The treatment paradigm for advanced non-small cell lung cancer (NSCLC) harboring EGFR mutations is undergoing a significant transition. While third-generation tyrosine kinase inhibitors (TKIs) like osimertinib have long served as the frontline standard, the em... ...
